SAGE Therapeutics Inc. (SAGE)

140.55
NASDAQ : Health Technology
Prev Close 135.97
Day Low/High 136.45 / 142.14
52 Wk Low/High 79.88 / 193.56
Avg Volume 383.50K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 7.02B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

Friday Wasn't Bad; Amazon-Induced Woes: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about Friday's positives and retail's woes.

CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

CORRECTING and REPLACING Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update

In the section Expected Near-Term Clinical Milestones, under Trial Initiations, the fourth bullet should read "Sage-217 in MDD" (instead of "Sage-547").

Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Sage Therapeutics To Report Third Quarter 2016 Financial Results On Thursday, November 3, 2016

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting

Sage Reports Additional Positive Data On Secondary Endpoints From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression At The Marcé Society For Perinatal Mental Health Biennial Scientific Meeting

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive results on secondary endpoints from...

Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable

Sage Therapeutics To Present At The Leerink Partners Rare Disease Roundtable

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics To Present At The Neurocritical Care Society 14th Annual Meeting

Sage Therapeutics To Present At The Neurocritical Care Society 14th Annual Meeting

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming poster presentations at the...

Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock

Sage Therapeutics Announces Pricing Of Public Offering Of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public...

'Mad Money' Lightning Round: I Believe in Walt Disney

'Mad Money' Lightning Round: I Believe in Walt Disney

Cramer is a fan of IBM and Tech Data.

Jim Cramer's 'Mad Money' Recap: The Perils of Competition

Jim Cramer's 'Mad Money' Recap: The Perils of Competition

When it comes to stock prices, competition has a lot of influence, Cramer says.

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten...

Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression

Sage Receives FDA Breakthrough Therapy Designation For SAGE-547 For The Treatment Of Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.

Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics

Sage Therapeutics And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the publication of a study conducted...

Short Interest In Sage Therapeutics Expands By 12.7%

Short Interest In Sage Therapeutics Expands By 12.7%

The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 463,924 share increase in total short interest for Sage Therapeutics Inc , to 4,131,029, an increase of 12.65% since 07/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss

SAGE Therapeutics (SAGE) Stock Closes Sharply Lower on 2Q Loss

SAGE Therapeutics (SAGE) reported wider losses for the second quarter before today's opening bell.

Sage Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update

Sage Therapeutics Announces Second Quarter 2016 Financial Results And Provides Corporate Update

Sage Therapeutics, Inc. (NASDAQ: SAGE) today reported business highlights and financial results for the second quarter ended June 30, 2016, and provided an update on corporate strategy and financial guidance.

Sage Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference

Sage Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics To Report Second Quarter 2016 Financial Results On Tuesday, August 9, 2016

Sage Therapeutics To Report Second Quarter 2016 Financial Results On Tuesday, August 9, 2016

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Sage Appoints Geno Germano To Company's Board Of Directors

Sage Appoints Geno Germano To Company's Board Of Directors

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced today that Geno Germano has been appointed to Sage's...

Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results

Sage Therapeutics (SAGE) CEO Jonas Tells CNBC He's 'Very Excited' By Positive Drug Results

Sage Therapeutics (SAGE) CEO Jeff Jonas told CNBC that the positive study results of the company's drug to treat postpartum depression are 'remarkable.'

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

SAGE Shares Surge After Postpartum Depression Drug Shows Promise

Shares of SAGE Therapeutics jumped after the company reported data from its SAGE-547 clinical trial for the treatment of severe postpartum depression.

Jim Cramer -- Sage Therapeutics Posts 'Remarkable Results'

Jim Cramer -- Sage Therapeutics Posts 'Remarkable Results'

Cramer says the drug could be huge but be alert for the stock rallying too far too fast.

Sage Therapeutics Drug Eliminates Postpartum Depression in Mid-Stage Trial

Sage Therapeutics Drug Eliminates Postpartum Depression in Mid-Stage Trial

The trial found 70% of women with postpartum depression treated with SAGE-547 achieved no more depression after 60 hours compared to just under 10% of women treated with placebo.

Sage Reports Positive Top-line Results Including Demonstration Of 30-Day Durability From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression

Sage Reports Positive Top-line Results Including Demonstration Of 30-Day Durability From Phase 2 Clinical Trial Of SAGE-547 In Severe Postpartum Depression

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced positive top-line results from its Phase 2...

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

A Biotech Stock Turnaround Requires an Alzheimer's Drug Miracle

What if the only sentiment-turning catalyst left for biotech stocks this year is the outcome of Eli Lilly's Alzheimer's phase III study expected around Christmas?

First Week of SAGE February 2017 Options Trading

First Week of SAGE February 2017 Options Trading

Investors in Sage Therapeutics Inc saw new options become available this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sage Therapeutics' Approach To GABA Receptor Drug Development

Sage Therapeutics' Approach To GABA Receptor Drug Development

Sage Therapeutics (NASDAQ:SAGE) today announced positive top-line results from its Phase 1 clinical program of SAGE-217, a novel, internally-developed orally active compound intended to enhance GABA receptor mediated...

Sage Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference

Sage Therapeutics To Present At The Goldman Sachs 37th Annual Global Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Biotech Stock Mailbag: Sage Therapeutics, Minerva

Biotech Stock Mailbag: Sage Therapeutics, Minerva

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

TheStreet Quant Rating: D (Sell)